COVID-19 vaccine effectiveness
(Randomized evidence)
Search studies
Trial | Type | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
---|---|---|---|---|---|---|---|---|
Intervention 1 | Intervention 2 | |||||||
ISRCTN69254139, EudraCT: 2020-005085-33 AstraZeneca+University of Oxford; Pfizer/BioNTech+Fosun Pharma Liu X, Lancet, 2022 Com-COV Full text Full text Commentary Commentary |
RNA based vaccine |
1 dose ChAdOx1/ 1 dose BNT162b2 1 dose BNT162b2 /1 dose ChAdOx1 |
2 doses ChAdOx1 2 doses BNT162b2 |
RCTPhase 2 | Adults 50 years or older with no previous SARS-CoV-2 infection, no or well-controlled mild-moderate comorbidities and HIV-negative in 8 centers in the UK | N= 463 |
Some concerns Details |
|
TCTR20210720007 Pfizer/BioNTech+Fosun Pharma; AstraZeneca+University of Oxford ;Sinovac Niyomnaitham S, Hum Vaccin Immunother, 2022 a Full text Commentary |
Heterologous vaccination scheme |
CoronaVac/ChAdOx1 CoronaVac/BNT162b2 ChAdOx1/CoronaVac ChAdOx1/BNT162b2 BNT162b2/CoronaVac BNT162b2+ChAdOx1 |
BNT162b2 |
RCTPhase 2 | Adults including healthy or stable co-morbidities that were SARS-CoV-2 infection-free in a single centre in Thailand. | N= 210 |
Some concerns Details |